Clinical Cancer Research: the 20th anniversary.

نویسندگان

  • Kenneth C Anderson
  • Jesse Potash
چکیده

Anniversary This year marks a milestone for Clinical Cancer Research (CCR)—we are celebrating our 20 th anniversary. CCR was launched in January 1995 by the American Association for Cancer Research (AACR), and at the time it was the third journal to join AACR's family of publications (following Cancer Research and Cancer Epidemiology, Biomarkers & Prevention). The journal was launched to report on research bridging the laboratory and the clinic, with the aim of providing a forum for high-impact trans-lational research in which molecular and cellular insights from the laboratory could be transformed into clinical interventions to manage and treat patients; it was part of AACR's overall plan to strengthen its commitment to clinical research. CCR was initially published once a month, and during its first year, 202 articles were published in the journal. Now CCR is published semimonthly, and in 2014 we published an impressive 696 articles. As the success of CCR grew over the years, so has the journal's Impact Factor. Most recently, our Impact Factor in 2013 was 8.193, the highest in the journal's history. We are very proud of what CCR has accomplished over the years. We would like to thank all of the editors and staff who have devoted their time and energy to the journal and, in particular, John Mendelsohn, who was the founding Editor-in-Chief (serving from 1995–2004), William N. Hait, who served as Editor-in-Chief from 2005– 2007, and Eric H. Rubin, who served as interim Editor-in-Chief during 2007. Over the past 20 years, a tremendous amount of progress has been made in our efforts to understand, diagnose, and treat cancer, and CCR has played an important role in helping to communicate important advances in clinical and translational oncology to the broader research community. To commemorate the 20 th anniversary of CCR, we have special content planned for 2015 to highlight some of the paradigm-shifting studies that have been published in CCR over the years. The editors of CCR have selected what we feel were some of the most significant studies that appeared in the journal since its inception, and we have asked the authors of those articles (or other leaders in the field) to write commentaries describing the impact of the research and how the field has continued to evolve since the publication of the studies. Given the long span of time covered by the journal and the many remarkable articles that have appeared …

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping.

In the August 15, 2004, issue of Clinical Cancer Research, Nielsen and colleagues demonstrated how a cancer subtype identified by gene expression profiling could be validated using a widely accessible technology (immunohistochemistry). This opened the door to large-scale studies of archival cohorts and clinical trials, which allowed detailed clinical understanding of a new genomic discovery. Cl...

متن کامل

CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.

The research article by Prewett and colleagues, published in the May 1, 2002, issue of Clinical Cancer Research, provided important translational data that extended earlier preclinical and clinical studies with the human-murine chimeric anti-EGFR monoclonal antibody C225. Subsequent clinical trials with C225 led to the demonstration of its efficacy in combination with irinotecan and regulatory ...

متن کامل

CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark.

The research article by Dent and colleagues, which was published in the August 1, 2007, issue of Clinical Cancer Research, provided a clinical description of metastatic progression of triple-negative breast cancers. Finding successful treatment strategies for women with triple-negative breast cancer remains a challenge.

متن کامل

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

In a study published in the May 1, 2001, issue of Clinical Cancer Research, Sunwoo and colleagues provided evidence for proteasome inhibition of NF-κB and tumorigenesis, supporting early-phase clinical trials in solid malignancies of the upper aerodigestive tract. Subsequent clinical studies uncovered a dichotomy of responses in patients with hematopoietic and solid malignancies, and the mechan...

متن کامل

CCR 20th Anniversary Commentary: Autologous T Cells-The Ultimate Personalized Drug for the Immunotherapy of Human Cancer.

The article by Rosenberg and colleagues, which was published in the July 1, 2011, issue of Clinical Cancer Research, demonstrated the power of the adoptive transfer of autologous antitumor T cells to mediate the complete, durable, and likely curative regression of cancer in patients with heavily pretreated metastatic melanoma. It also provided a stimulus to the development of cell transfer appr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical cancer research : an official journal of the American Association for Cancer Research

دوره 21 1  شماره 

صفحات  -

تاریخ انتشار 2015